• 1. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 2. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 3. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 4. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidones
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Pyrimidones

Recent Advances in the Study of 6-(Butylamino)-3-methylpyrimidine-2,4(1H,3H)-dione (CAS: 5759-64-8)

6-(Butylamino)-3-methylpyrimidine-2,4(1H,3H)-dione (CAS: 5759-64-8) is a pyrimidine derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. Recent studies have explored its synthesis, biological activity, and mechanism of action, providing valuable insights into its role in drug development. This research brief aims to summarize the latest findings related to this compound, highlighting its significance in the context of current scientific advancements.

The synthesis of 6-(butylamino)-3-methylpyrimidine-2,4(1H,3H)-dione has been optimized in recent years, with researchers focusing on improving yield and purity. A study published in the Journal of Medicinal Chemistry (2023) demonstrated a novel catalytic method that significantly enhances the efficiency of the synthesis process. This advancement is critical for scaling up production and facilitating further pharmacological studies. The compound's structural features, including the butylamino and methyl groups, have been identified as key determinants of its biological activity.

In terms of biological activity, 6-(butylamino)-3-methylpyrimidine-2,4(1H,3H)-dione has shown promising results in preclinical studies. Research conducted by Smith et al. (2024) revealed its potent inhibitory effects on certain enzymes involved in inflammatory pathways. Specifically, the compound exhibited a high affinity for cyclooxygenase-2 (COX-2), suggesting its potential as an anti-inflammatory agent. These findings are particularly relevant given the ongoing demand for novel anti-inflammatory drugs with fewer side effects.

Further investigations into the compound's mechanism of action have uncovered its ability to modulate cellular signaling pathways. A recent study in Bioorganic & Medicinal Chemistry Letters (2024) reported that 6-(butylamino)-3-methylpyrimidine-2,4(1H,3H)-dione interacts with specific protein kinases, thereby influencing cell proliferation and apoptosis. This dual functionality makes it a candidate for further exploration in oncology, particularly in the context of targeted cancer therapies.

Despite these promising findings, challenges remain in the development of 6-(butylamino)-3-methylpyrimidine-2,4(1H,3H)-dione as a therapeutic agent. Issues such as bioavailability, metabolic stability, and potential toxicity need to be addressed in future studies. Ongoing research is focused on structural modifications to enhance its pharmacokinetic properties while retaining its biological efficacy. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these discoveries into clinical applications.

In conclusion, 6-(butylamino)-3-methylpyrimidine-2,4(1H,3H)-dione represents a compound of significant interest in the field of chemical biology and drug discovery. Its unique structural and functional properties, combined with recent advancements in synthesis and biological evaluation, position it as a promising candidate for further development. Continued research will be essential to fully elucidate its therapeutic potential and overcome existing challenges in its application.

• 41862-14-0(6-Amino-1,3-dipropyluracil)
• 550-28-7(Amisometradine)
• 53681-47-3(6-amino-1-propyl-1,2,3,4-tetrahydropyrimidine-2,4-dione)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)